NCT01788774View on ClinicalTrials.gov

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Risperidone ISM 50 mg

DRUG

Risperidone ISM 75 mg

DRUG

Risperidone ISM 100 mg

Trial Locations (5)

Unknown

Zagreb

Moscow

Saint Petersburg

Cape Town

Barcelona

All Listed Sponsors
lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT01788774 - Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths | Biotech Hunter | Biotech Hunter